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The impact of the absolute number and ratio of positive lymph
nodes on survival of endometrioid uterine cancer patients
JK Chan*,1, DS Kapp2, MK Cheung3, K Osann4, JY Shin3, D Cohn5 and PL Seid2
1Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of
Medicine, San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, Box 1702, San Francisco, CA 94143, USA; 2 Division of Radiation
Therapy, Department of Radiation Oncology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, MC 5827,
Stanford, CA 94305, USA; 3Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford
Cancer Center, 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA; 4Division of Hematology and Oncology Department of Medicine, , Chao
Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA; 5Division of
Gynecologic Oncology, Department of Obsetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, Ohio State University College
of Medicine and Public Health, M210 Starling-Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210, USA
The aim of the study was to determine the impact of the absolute number and ratio of positive lymph nodes on the survival in node-
positive endometrioid uterine cancer. Data were obtained from the National Cancer Institute Registry from 1988 to 2001. Analyses
were performed using Kaplan–Meier and Cox proportional hazard methods. A total of 1222 women were diagnosed with stage IIIC-
IV node-positive endometrioid corpus cancer. The 5-year disease-specific survival of women with 1, 2–5, and 45 positive nodes
were 68.1, 55.1, and 46.1%, respectively (Po0.001). Increasing lymph node ratio, expressed as a percentage of positive nodes to total
nodes identified (p10, 410–p50, and 450%), was associated with a decrease in survival from 77.3 to 60.7 to 40.9%, respectively
(Po0.001). The absolute number of positive nodes and the lymph node ratio remained significant after adjusting for stage (IIIC vs IV)
and the extent of lymphadenectomy (p20 vs 420 nodes). On multivariate analysis, the absolute number of positive nodes and
lymph node ratio were significant independent prognostic factors for survival. Increasing absolute number of positive nodes and
lymph node ratio are associated with a poorer survival in women with node-positive uterine cancers. The stratification of node-
positive uterine cancer for prognostic and treatment purposes warrants further investigation.
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Endometrial carcinoma is the most common gynaecological
malignancy in the United States with an expected 7350 deaths
associated with this disease in 2006 (Jemal et al, 2006). Although
approximately 80% of patients are diagnosed with early-stage
(I–II) disease and have an excellent prognosis, women with advanced-
stage (III –IV) cancers have significantly poorer outcome. Meta-
static involvement of retroperitoneal lymph nodes is one of the
most important prognostic factors (Morrow et al, 1991). Of the
patients with node-positive disease, the estimated 5-year disease-
specific survival ranges from 10 to 75% (Potish et al, 1985; Larson
et al, 1987; Lurain et al, 1991; Morrow et al, 1991; Rose et al, 1992;
Greven et al, 1993; Schorge et al, 1996; Nelson et al, 1999; Mariani
et al, 2002; Watari et al, 2005; Chan et al, 2006; Randall et al, 2006).
The wide range of outcomes suggests that there exists considerable
heterogeneity in these node-positive patients based on various
clinicopathological prognostic factors. Furthermore, over 50% of
stage III– IV disease patients fail standard treatments with either
whole abdominal radiation or chemotherapy and experience
significant toxicities (Bruner et al, 2006; Randall et al, 2006).
Studies focused on defining these prognostic factors may permit
better substage stratification and determine novel treatment
strategies. For example, multi-modality therapies should be
designed for high-risk patients to improve survival and indivi-
dualised tailored therapies are preferred in low-risk patients to
prevent toxicities associated with over-treatment.
The association between the extent of lymph node involvement
and survival has been demonstrated in most solid tumours
including lung, breast, colon, rectal, bladder, cervical, and vulva
cancers (van der Velden et al, 1995; Moore and Stehman, 1996;
Tepper et al, 2001; Herr et al, 2002; Weir et al, 2002; Gajra et al,
2003; Joseph et al, 2003; Le Voyer et al, 2003). Furthermore, the
number of nodal metastases in breast cancer is not only used as a
prognostic tool but it also guides adjuvant treatment (NCCN,
2006). However, the current staging system for uterine cancer
under International Federation of Gynecology and Obstetrics
(FIGO) does not account for the extent of nodal disease. Prior
studies have shown that patients with stage IIIC uterine cancer
limited only to the pelvic nodes have significantly better prognosis
than for other subgroups of stage IIIC disease, suggesting that
stratification may be appropriate (Morrow et al, 1991; Nelson et al,
1999; Mariani et al, 2002; Watari et al, 2005).
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In this present study, we determined the prognostic significance
of the absolute number and ratio of positive lymph nodes in
endometrioid uterine cancer. Furthermore, we identified other
clinicopathological prognostic factors important in node-positive
corpus cancer.
PATIENTS AND METHODS
Demographic, clinicopathological, treatment, and survival infor-
mation of women diagnosed with endometrioid corpus cancer
during the period from 1 January 1988 to 31 December 2001 was
extracted with permission from the Surveillance, Epidemiology
and End Results (SEER) programme of the United States National
Cancer Institute (Surveillance, 2005). This data represent approxi-
mately 14% of the US population and is reported from 12
population-based registries including San Francisco-Oakland,
Connecticut, metropolitan Detroit, Hawaii, Iowa, New Mexico,
Seattle (Puget Sound), Utah, metropolitan Atlanta, Alaska, San
Jose-Monterey, and Los Angeles.
Of the 40 880 women diagnosed with endometrioid uterine
cancer, 1222 patients had stage IIIC –IV disease with at least one
positive pelvic and/or paraaortic lymph node. All patients under-
went surgical staging including lymphadenectomy. Information
regarding patient age, stage, tumour grade, number of positive
lymph nodes, extent of lymph node dissection (defined as the
total number of lymph nodes recovered), and use of adjuvant
radiation therapy was extracted. Patients were divided into
three nodal groups (1, 2 –5, and 45 positive nodes). The lymph
node ratio, expressed as the percentage of positive nodes to
total nodes identified, was stratified into three groups (p10,
410–p50, and 450%).
Statistical analysis was performed using the Intercooled STATA
8.0 program (College Station, TX). Survival analysis was performed
using the Kaplan–Meier method. The outcome of interest was
death from endometrial cancer. Time to death was censored in
women who died from causes other than uterine cancer. The Cox
proportional hazards model was used to identify independent
predictors of survival. A forward stepwise model was used to
determine which prognostic variable was more important for
prediction of outcome. Two-tailed tests at P-values less than 0.05
were considered significant.
RESULTS
Patient characteristics of 1222 women diagnosed with stage
IIIC–IV node-positive endometrioid uterine cancer are shown in
Table 1. The median age at diagnosis was 64 years (range: 28– 93
years). 639 (52.3%) were stage IIIC, 24 (2.0%) were stage IVA, and
559 (45.7%) were stage IVB. The median number of lymph nodes
removed was 11 (range: 1– 90). The median number of positive
lymph nodes was 2 (range: 1 –52) and the median lymph node
ratio was 23.2% (range: 1.8–100%). The 5-year disease-specific
survivals of patients with stage IIIC and IV were 70.3 and 47.8%,
respectively (Po0.001). A more extensive lymphadenectomy
(Po0.001), lower grade tumours (Po0.001), and use of radio-
therapy (Po0.001) were associated with an improved survival
(Table 2).
When all patients were divided into three groups based on the
number of positive lymph nodes (1, 2–5, and 45 positive nodes),
the 5-year disease-specific survival decreased from 68.1 to 55.1
to 46.1%, respectively (Po0.001; Figure 1). Adjusted for stage of
disease, the association between absolute number (1, 2 –5, and
45) of positive nodes and survival rates were 77.1, 60.9, and
69.1%, respectively (P¼ 0.003) in patients with stage IIIC disease
and 50.9, 49.8, and 38.9%, respectively (P¼ 0.099) in stage IV
cancers (Figure 2A and C). The prognostic significance of the
absolute number of positive nodes was also examined based on the
extent of lymphadenectomy. In those with p20 nodes identified,
the absolute number (1, 2 –5, and 45) of positive nodes was
associated with a decrease in survival from 65.1 to 50 to 29.7%,
respectively (Po0.001). In addition, women with 420 nodes
identified had an associated decrease in survival from 82.6 to 71.9
to 59.7%, respectively (P¼ 0.047; Figure 3A and C) for the three
positive nodal groups.
Increasing lymph node ratio (p10, 410–p50, and 450%) was
associated with a decrease in 5-year disease-specific survival
from 77.3 to 60.7 to 40.9%, respectively (Po0.001; Figure 1). For
patients with stage IIIC disease, survival decreased from 78.6 to
66.5 to 65.3%, corresponding to the three lymph node ratio groups
(P¼ 0.025), and this finding was consistent in stage IV cancers
with associated survival rates of 73.8 to 53.3 to 30.1%, respectively
(Po0.001; Table 2 and Figure 2B and D). We also divided the study
group based on the extent of lymphadenectomy and found that the
group with p20 nodes resected had associated survivals of 73.5,
60.1, and 39.5%, for the three corresponding lymph node ratio
Table 1 Clinicopathological Characteristics of Patients with Node-
Positive Endometrioid Uterine Cancer (n¼ 1222)
Parameters n (%)
Age (years)
o65 626 (51.2%)
X65 596 (48.8%)
Race
White 1025 (83.9%)
Black 75 (6.1%)
Asian 91 (7.4%)
Other 31 (2.5%)
Year of diagnosis
1988–1992 230 (18.8%)
1993–1997 455 (37.2%)
1998–2001 537 (43.9%)
Stage
Stage IIIC 639 (52.3%)
Stage IV 583 (47.7%)
Stage IVA 24 (2.0%)
Stage IVB 559 (45.7%)
Grade
Grade 1 123 (10.0%)
Grade 2 466 (38.1%)
Grade 3 581 (47.5%)
Unknown 52 (4.3%)
Radiation
No XRT 423 (34.6%)
Adjuvant XRT 772 (63.2%)
Unknown 27 (2.2%)
Number nodes removed
p10 582 (47.6%)
11–20 320 (26.2%)
420 320 (26.2%)
Number of metastatic nodes
1 positive node 529 (43.3%)
2–5 positive nodes 547 (44.8%)
45 positive nodes 146 (11.9%)
Lymph node ratio (%)
p10 306 (25.0%)
410–p50 622 (50.9%)
450 294 (24.1%)
Abbreviation: XRT, radiotherapy.
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groups, respectively (Po0.001). Similarly, those with 420 nodes
resected had survival rates of 80.6, 62.9, and 57.6% (P¼ 0.052;
Figure 3B and D). The impact of the absolute number and ratio of
positive nodes by stage, grade of disease, radiation therapy, and
extent of lymphadenectomy on survival is summarised in Table 2.
On multivariate analysis, the absolute number of positive lymph
nodes (P¼ 0.005) and the lymph node ratio (P¼ 0.003) were
independent prognostic factors for survival adjusting for age,
stage, grade of disease, year of diagnosis, adjuvant radiation, and
extent of lymphadenectomy (Table 3). Hazard ratios were higher
for patients with more than 5 positive nodes relative to those
with 2 –5 positive or 1 positive node (HR¼ 1.63 vs 1.28 vs 1.0,
respectively). Moreover, the hazard ratio was significantly higher
for each percent increase in lymph node ratio (HR¼ 1.05 for a 10%
increase in lymph node ratio). Correlation between these variables
was relatively small (r¼ 0.2), thus each contributed independently
to the prediction of the hazard rate. In forward stepwise
regression, lymph node ratio entered the model before absolute
number of positive nodes suggesting an overall greater prognostic
ability. However, when the analysis is restricted to patients with
less extensive lymphadenectomy (p10 nodes), only the absolute
number of positive nodes contributed significantly to prediction
of survival (P¼ 0.005 for absolute number of positive nodes;
P¼ 0.186 for lymph node ratio).
DISCUSSION
Advanced stage uterine cancer continues to be a significant cause
of death among gynaecological cancers in the United States (Jemal
et al, 2006). Prior studies have found that stage IIIC node-positive
endometrial cancers comprise of only 2–6% of all cases (Creasman
et al, 1987; Lurain et al, 1991; Morrow et al, 1991; Greven et al,
1993; Schorge et al, 1996; Faught et al, 1998). Given that it is
difficult for institutions to collect a large series of women with
node-positive uterine cancer, this subgroup of patients has not
been well studied. In addition, the prognostic factors in these
high-risk patients have not been extensively characterised. In this
current series of 1222 women with node-positive endometrioid
uterine cancer, we determined the prognostic significance of the
absolute number and ratio of positive nodes. In addition, this is
one of the first papers that compared the prognostic significance of
lymph node ratio to absolute number of positive nodes in patients
with endometrial cancer.
Since women with node-positive endometrioid uterine cancer
have a wide range of survival from 10 to 75% (Potish et al, 1985;
Larson et al, 1987; Lurain et al, 1991; Morrow et al, 1991; Rose
et al, 1992; Greven et al, 1993; Schorge et al, 1996; Faught et al,
1998; Nelson et al, 1999; Mariani et al, 2002; Watari et al, 2005;
Chan et al, 2006; Randall et al, 2006), several investigators have
suggested substaging these patients (Nelson et al, 1999; Mariani
et al, 2002; Watari et al, 2005). In this current report, our findings
support the concept of stratifying node-positive cancers into
substages based on nodal burden. The 5-year disease-specific
survival of this heterogeneous cohort of node-positive patients in
our study ranges from approximately 40 to 77%.
The prognostic significance of the absolute number and/or ratio
of positive nodes has been reported in other solid tumours (van
der Velden et al, 1995; Moore and Stehman, 1996; Tepper et al,
2001; Bando et al, 2002; Herr et al, 2002; Weir et al, 2002; Gajra
et al, 2003; Joseph et al, 2003; Le Voyer et al, 2003; Berger et al,
2005; Sierzega et al, 2006). In breast cancer, the nodal ratio has
been shown to be an important predictor of loco-regional
recurrence and survival both from initial diagnosis and following
recurrence (Nieto et al, 2002; Grills et al, 2003; Woodward et al,
2006). Several studies compared the prognostic value of nodal
ratios to the absolute number of positive nodes and found that
lymph node ratio had a stronger prognostic value in breast cancer
(Vinh-Hung et al, 2004; Woodward et al, 2006).
Small retrospective studies from single institutions have
evaluated the significance of the absolute number and ratio of
positive nodes in uterine cancers. Mariani et al (2001) studied 60
patients with endometrial cancer with pelvic nodal metastases.
These authors found that patients who recurred or died of disease
had a higher percentage of positive lymph nodes at presentation.
Similarly, Tang et al(1998) evaluated 40 patients with pelvic and/or
paraaortic nodal metastases and found a 5-year disease-specific
survival of 0 vs 55% in those withX25 vso25% lymph node ratio.
Yasunaga et al(2003) have also shown that a high metastatic ratio
is associated with a lower survival. Patients with lymph node ratios
of o10, 10– 50, and 450% had 5-year survival rates of 82.5, 43.8,
and 0%, respectively (Yasunaga et al, 2003). However, these studies
were limited by the small sample sizes and inclusion of high-risk
cell types such as serous and clear cell cancers. More importantly,
there may exist a potential selection bias due to reporting from
tertiary care academic centres caring for high-risk patients. Thus,
these small study cohorts may not be representative of the general
population. Furthermore, these studies did not compare the
prognostic importance of nodal ratio to the absolute number of
positive nodes, likely due to the limitations in sample size.
On multivariate analysis of the 1222 node-positive patients in
this current study, the absolute number (P¼ 0.005) and lymph
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Figure 1 Kaplan–Meier disease-specific survival of node-positive endometrioid uterine cancer based on (A) absolute number (1, 2–5, and 45) of
positive nodes: 68.1, 55.1, and 46.1%; Po0.001, and (B) ratio of positive lymph nodes (p10, 410–p50, and 450%): 77.3, 60.7, and 40.9%; Po0.001.
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node ratio (P¼ 0.003) remained as independent prognostic factors
after adjusting for age, stage, grade of disease, and extent of lymph
node dissection. The correlation between the categorical variables,
absolute number and ratio of positive nodes, was relatively small
and thus both variables were independent predictors for survival.
Analysed as a continuous variable, lymph node ratio entered the
proportional hazard model before absolute number of positive
nodes in stepwise regression suggesting that the lymph node ratio
may better characterise prognostic subgroups than the number of
positive nodes. In addition, Kaplan–Meier analyses provide
further support showing a larger separation of curves depicted in
the overall study group (Figure 1) and substages of IIIC vs IV
cancers (Figure 2).
Compared to the absolute number of positive lymph nodes, the
lymph node ratio may be a better predictor of tumour burden and
aggressive biological behaviour of the tumour, particularly in those
who had a more extensive lymphadenectomy. As such, the survival
differences within these subgroups by lymph node ratio were more
pronounced. However, in patients with a limited number of lymph
nodes recovered, the absolute number of positive nodes appears
to be a better predictor. It is important to note that the number
of nodes recovered may reflect a more extensive dissection,
comprehensiveness of pathological evaluation, variations in
number of nodes of each patient, and difficulties in performing
lymphadenectomies due to medical comorbidities (Yasunaga
et al, 2003).
The majority of stage III –IV uterine cancer patients fail
standard chemotherapy or whole abdominal radiation (Randall
et al, 2006). It would be important to identify the patients at
particularly high risk of recurrence in whom a combination of
chemotherapy and radiation therapy may be beneficial, while
sparing lower-risk patients from the toxicity of excessive therapy
(Bruner et al, 2006). Extrapolating from breast cancer treatment
recommendations, it may be possible that tailored therapy can be
selected based on stratifying patients with node-positive uterine
cancer into various risk groups. For example, local irradiation may
be adequate for those with low numbers of lymph nodes involved,
particularly if a thorough lymphadenectomy was performed.
In contrast, higher-risk patients with a larger nodal tumour
burden may warrant more extensive treatment including systemic
chemotherapy combined with site-specific irradiation. In
fact, a current Gynecologic Oncologic Group trial is investigating
the role of multi-modality therapy in advanced uterine cancer to
define the optimal chemotherapy combined with radiation
(Homesley et al, 2000).
The finding that the overall number of lymph nodes removed at
surgery correlates with survival has been previously reported
(Kilgore et al, 1995; Blythe et al, 1997; McMeekin et al, 2001; Chan
et al, 2006; Lutman et al, 2006; Mariani et al, 2006). In early-stage
disease, it is not clear whether this benefit is due directly to
cytoreductive effects of surgery or from more accurate staging.
In this current study of node-positive patients, we found that a
more extended dissection remained as an important predictor for
survival after controlling for the absolute number and ratio of
positive nodes. The improvement in survival associated with
extent of lymph node resection and possible mechanisms have
been previously reported (Chan et al, 2006). Lastly, it is possible
that lymph node dissection may be a surrogate for the quality
comprehensive care rather than the cause that resulted in the
better outcome of these patients.
Our study has several recognisable limitations. There is a lack
of information on surgeon sub-specialty, comprehensive surgical
staging, central pathology review, adjuvant hormonal and chemo-
therapy, time to recurrence, subsequent surgical and medical
therapies, and surgical morbidity. Additionally, there was limited
data on the specific laterality and location of nodal resection.
Moreover, our data do not have detailed information regarding the
depth of myometrial invasion, peritoneal cytology, extent of nodalT
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Figure 2 Kaplan–Meier disease-specific survival based of stage IIIC (A and B) vs stage IV (C and D) disease by absolute number (A and C) and ratio
(B and D) of positive lymph nodes.
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Figure 3 Kaplan–Meier disease-specific survival based on extent of node dissectionp20 nodes (A and B) vs420 nodes (C and D) disease by absolute
number (A and C) and ratio (B and D) of positive lymph nodes.
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debulking, and extent of extrauterine involvement associated with
the node-positive cancer. It is conceivable that the extent of
extrauterine involvement may be strongly correlated with the
lymph node burden and thus confound our findings.
The strengths of this study include the fact that this is one of the
largest studies evaluating the impact of nodal burden and
lymphadenectomy on the survival of node-positive endo-
metrioid uterine cancer. In addition, all patients with high-risk
cell types such as papillary serous, clear cell, and sarcomas
were excluded from the analyses. The wide geographical distri-
bution of patients including 12 US regions also decreases the
potential selection and surveillance biases that are associated
with single-institution analyses (Surveillance, 2005). Furthermore,
the results from this population-based study can be generalised
to the entire US population. The quality control measures of
the SEER programme allow the registry to maintain the highest
level of certification of data quality and completeness reported
by the Northern American Association of Central Cancer
Registries.
In summary, improving risk assessments in advanced endo-
metrial cancers beyond the current FIGO staging definition is of
particular interest as the treatment of high-risk uterine cancers
evolves. The sub-classification of node-positive cancers based on
the absolute number and ratio of positive nodes may assist the
physician to better define prognosis and more importantly, stratify
patients into various risk groups in the design of future clinical
trials. If confirmed in a prospective clinical trial, these findings
may ultimately modify the current staging system and lead to
individualised tailored therapies in patients with node-positive
uterine cancer.
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